These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2134015)

  • 1. Synthetic peptides: prospects for vaccine development.
    Milich DR
    Semin Immunol; 1990 Sep; 2(5):307-15. PubMed ID: 2134015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic peptide interaction with MHC molecules: implications for the design of artificial vaccines.
    Berzofsky JA
    Semin Immunol; 1991 Jul; 3(4):203-16. PubMed ID: 1932704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
    Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
    J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design.
    Purcell AW; Zeng W; Mifsud NA; Ely LK; Macdonald WA; Jackson DC
    J Pept Sci; 2003 May; 9(5):255-81. PubMed ID: 12803494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Plasmodium falciparum circumsporozoite peptides elicit heterogenous L3T4+ T cell proliferative responses in H-2b mice.
    Togna AR; Del Giudice G; Verdini AS; Bonelli F; Pessi A; Engers HD; Corradin G
    J Immunol; 1986 Nov; 137(9):2956-60. PubMed ID: 2428881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic peptides: a modern approach to vaccination.
    Sood A; Venugopalan P; Mysore N; Vyas SP
    Indian J Exp Biol; 1998 Sep; 36(9):849-61. PubMed ID: 9854423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral peptide immunogens: current challenges and opportunities.
    Azizi A; Diaz-Mitoma F
    J Pept Sci; 2007 Dec; 13(12):776-86. PubMed ID: 17853502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and development of synthetic peptide vaccines: past, present and future.
    Bijker MS; Melief CJ; Offringa R; van der Burg SH
    Expert Rev Vaccines; 2007 Aug; 6(4):591-603. PubMed ID: 17669012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic peptides as cancer vaccines.
    Sundaram R; Dakappagari NK; Kaumaya PT
    Biopolymers; 2002; 66(3):200-16. PubMed ID: 12385038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor antigens and tumor vaccines: peptides as immunogens.
    Slingluff CL
    Semin Surg Oncol; 1996; 12(6):446-53. PubMed ID: 8914209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase.
    Reynolds SR; Dahl CE; Harn DA
    J Immunol; 1994 Jan; 152(1):193-200. PubMed ID: 7504709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic peptides as vaccines.
    Rothbard J
    Nature; 1987 Nov 12-18; 330(6144):106-7. PubMed ID: 3499571
    [No Abstract]   [Full Text] [Related]  

  • 13. Peptide mimotopes as candidate vaccines.
    Partidos CD
    Curr Opin Mol Ther; 2000 Feb; 2(1):74-9. PubMed ID: 11249654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.
    van der Burg SH; Bijker MS; Welters MJ; Offringa R; Melief CJ
    Adv Drug Deliv Rev; 2006 Oct; 58(8):916-30. PubMed ID: 16979788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment in mice of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, P. falciparum.
    Etlinger HM; Heimer EP; Trzeciak A; Felix AM; Gillessen D
    Immunology; 1988 Jul; 64(3):551-8. PubMed ID: 3044983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.
    Berzofsky JA; Bensussan A; Cease KB; Bourge JF; Cheynier R; Lurhuma Z; Salaün JJ; Gallo RC; Shearer GM; Zagury D
    Nature; 1988 Aug; 334(6184):706-8. PubMed ID: 2457809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More than one reason to rethink the use of peptides in vaccine design.
    Purcell AW; McCluskey J; Rossjohn J
    Nat Rev Drug Discov; 2007 May; 6(5):404-14. PubMed ID: 17473845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New technology of vaccine production--international prospect of the development. Synthetic peptide vaccines and protein engineering].
    Aimoto S; Sakiyama F
    Nihon Rinsho; 1987 Oct; 45(10):2349-54. PubMed ID: 3502349
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetic considerations in the design of a malaria vaccine.
    Rzepczyk CM
    P N G Med J; 1989 Dec; 32(4):251-8. PubMed ID: 2483292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice.
    Fifis T; Mottram P; Bogdanoska V; Hanley J; Plebanski M
    Vaccine; 2004 Nov; 23(2):258-66. PubMed ID: 15531045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.